Natural Product (NP) Details
General Information of the NP (ID: NP8937) | |||||
---|---|---|---|---|---|
Name |
Pinocembrin
|
||||
Synonyms |
Pinocembrin; 480-39-7; (+)-Pinocembrin; (2S)-pinocembrin; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-phenyl-, (2S)-; (S)-5,7-dihydroxy-2-phenylchroman-4-one; UNII-8T7C8CH791; (2s)-5,7-dihydroxy-2-phenyl-2,3-dihydro-4h-chromen-4-one; (S)-5,7-dihydroxyflavanone; CHEMBL399910; CHEBI:28157; (S)-2,3-Dihydro-5,7-dihydroxy-2-phenyl-4H-1-benzopyran-4-one; 8T7C8CH791; Pinocembrin (6CI); (2S)-5,7-dihydroxy-2-phenyl-3,4-dihydro-2H-1-benzopyran-4-one; SMR000232372; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-phenyl-, (-)-; NSC 43318; NSC 279005; NSC 661207; NSC43318; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-phenyl-, (S)-; NSC-43318; NSC661207; NSC-279005; Spectrum_001879; SpecPlus_000896; Spectrum2_001670; Spectrum3_001635; Spectrum4_001765; Spectrum5_000349; Oprea1_508274; BSPBio_003329; KBioGR_002249; KBioSS_002406; MLS000697595; MLS000728654; DivK1c_006992; SPBio_001859; DTXSID3075412; SCHEMBL10026578; BDBM26667; KBio1_001936; KBio2_002401; KBio2_004969; KBio2_007537; KBio3_002549; ZINC73693; HMS2205J20; HY-N0575; CCG-39668; LMPK12140214; s3941; STL578139; AKOS004111068; SDCCGMLS-0066749.P001; NCGC00178137-01; AS-56293; ST023293; (2S)-5,7-dihydroxy-2-phenylchroman-4-one; CS-0009111; (2S)-5,7-dihydroxy-2-phenyl-chroman-4-one; C09827; SR-01000762561; SR-01000762561-3; BRD-K94689771-001-02-5; Pinocembrin, analytical standard, 95% (TLC), solid; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-phenyl-, (S)-(-)-
Click to Show/Hide
|
||||
Species Origin | Eucalyptus ... | Click to Show/Hide | |||
Eucalyptus | |||||
Disease | Ischemic stroke [ICD-11: 8B11] | Phase 2 | [1] | ||
Structure |
![]() |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C15H12O4
|
||||
PubChem CID | |||||
Canonical SMILES |
C1C(OC2=CC(=CC(=C2C1=O)O)O)C3=CC=CC=C3
|
||||
InChI |
1S/C15H12O4/c16-10-6-11(17)15-12(18)8-13(19-14(15)7-10)9-4-2-1-3-5-9/h1-7,13,16-17H,8H2/t13-/m0/s1
|
||||
InChIKey |
URFCJEUYXNAHFI-ZDUSSCGKSA-N
|
||||
CAS Number |
CAS 480-39-7
|
||||
ChEBI ID | |||||
Herb ID | |||||
SymMap ID | |||||
TCMSP ID | |||||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Simvastatin | Hyper-lipoproteinaemia | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
|
In-vivo Model | ApoE / mice (8 weeks old) were fed a high fat diet (21% fat and 0.15% cholesterol). | |||||
Experimental
Result(s) |
The combination of simvastatin and pinocembrin synergistically inhibited atherosclerotic lesion development in ApoE-/- mice with hyperlipidemia, which is partially dependent on the protective of vascular endothelium. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Cytochrome P450 1B1 (CYP1B1) | Molecule Info | [3] | |
BioCyc | Superpathway of tryptophan utilization | Click to Show/Hide | ||
2 | Superpathway of melatonin degradation | |||
3 | Melatonin degradation I | |||
KEGG Pathway | Steroid hormone biosynthesis | Click to Show/Hide | ||
2 | Tryptophan metabolism | |||
3 | Metabolism of xenobiotics by cytochrome P450 | |||
4 | Ovarian steroidogenesis | |||
5 | Chemical carcinogenesis | |||
6 | MicroRNAs in cancer | |||
NetPath Pathway | TSH Signaling Pathway | Click to Show/Hide | ||
2 | IL4 Signaling Pathway | |||
3 | TGF_beta_Receptor Signaling Pathway | |||
Reactome | Endogenous sterols | Click to Show/Hide | ||
WikiPathways | Metapathway biotransformation | Click to Show/Hide | ||
2 | Estrogen metabolism | |||
3 | Benzo(a)pyrene metabolism | |||
4 | Tamoxifen metabolism | |||
5 | Tryptophan metabolism | |||
6 | Oxidation by Cytochrome P450 | |||
7 | Nuclear Receptors Meta-Pathway | |||
8 | Estrogen Receptor Pathway | |||
9 | Sulindac Metabolic Pathway | |||
10 | Arylhydrocarbon receptor (AhR) signaling pathway | |||
11 | miR-targeted genes in muscle cell - TarBase | |||
12 | miR-targeted genes in lymphocytes - TarBase | |||
13 | miR-targeted genes in epithelium - TarBase | |||
14 | miR-targeted genes in adipocytes - TarBase | |||
15 | Phase 1 - Functionalization of compounds |
